News

Image source: The Motley Fool.

Biogen (NASDAQ: BIIB)Q2 2023 Earnings CallJul 25, 2023, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

There are several reasons many investors gravitate toward dividend stocks. Some are attracted to the regular income stream, while others opt for dividend reinvestment to boost long-term returns

Achieving success as a growth investor revolves around picking companies that are taking new and potentially winning approaches to solving existing problems. These businesses can take their place as

Since no two investors have the same plans and levels of risk tolerance, no two investment portfolios will be identical to each other. Although the goal for all investors is to build enough wealth

Shares of Becton, Dickinson (NYSE: BDX) were up by more than 6% as of 12:15 p.m. ET Monday, after having climbed by as much as 8.5% shortly after 10 a.m. The medical equipment company announced

When you think of biotech companies, you may think of up-and-coming players with exciting pipelines, but zero marketed products. These could make interesting investment opportunities. But they often

When you think of biotech companies, you may think of up-and-coming players with exciting pipelines, but zero marketed products. These could make interesting investment opportunities. But they often

When you think of biotech companies, you may think of up-and-coming players with exciting pipelines, but zero marketed products. These could make interesting investment opportunities. But they often

Think small. It's one of the best ideas for investors seeking to reap returns that trounce the overall market.

Three Motley Fool contributors identified small-cap stocks that they think could

Even if you don't recognize the name Viatris (NASDAQ: VTRS), you may have come in very close contact with this pharma company. It sells a wide variety of generic drugs -- such as generic Zyrtec

Even if you don't recognize the name Viatris (NASDAQ: VTRS), you may have come in very close contact with this pharma company. It sells a wide variety of generic drugs -- such as generic Zyrtec

Investors looking for stocks with explosive growth potential would do well to take a gander at the biotech industry. Clinical and regulatory wins can fuel excellent stock market performances for

Investors looking for stocks with explosive growth potential would do well to take a gander at the biotech industry. Clinical and regulatory wins can fuel excellent stock market performances for

Investors looking for stocks with explosive growth potential would do well to take a gander at the biotech industry. Clinical and regulatory wins can fuel excellent stock market performances for

CRISPR Therapeutics (NASDAQ: CRSP) may be a few months away from a transformation. The company itself isn't changing, but its financial picture may be about to do so. That's because by year-end

CRISPR Therapeutics (NASDAQ: CRSP) may be a few months away from a transformation. The company itself isn't changing, but its financial picture may be about to do so. That's because by year-end

CRISPR Therapeutics (NASDAQ: CRSP) may be a few months away from a transformation. The company itself isn't changing, but its financial picture may be about to do so. That's because by year-end

Image source: The Motley Fool.

Abbott Laboratories (NYSE: ABT)Q2 2023 Earnings CallJul 20, 2023, 9:30 a.m. ET

Operator

Continue reading

Source Fool.com

Over the past three years, Novavax (NASDAQ: NVAX) has lost an astonishing 92% of its value on the market. The reason for that is no secret. The biotech quickly established itself in the race to

There's no healthcare company that's worth anywhere near $1 trillion today. But within the next 10 years, that's likely to change, given the many growth opportunities emerging in the industry. Two